These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32147955)

  • 21. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
    Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
    Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials.
    Hwang IC; Kim YJ; Park JB; Yoon YE; Lee SP; Kim HK; Cho GY; Sohn DW
    BMC Cardiovasc Disord; 2017 Jun; 17(1):150. PubMed ID: 28606099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nitric oxide inhalation reduces pulmonary tidal volume during exercise in severe chronic heart failure.
    Bocchi EA; Auler JO; Guimarães GV; Carmona MJ; Wajngarten M; Bellotti G; Pileggi F
    Am Heart J; 1997 Oct; 134(4):737-44. PubMed ID: 9351742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physiological dead space and arterial carbon dioxide contributions to exercise ventilatory inefficiency in patients with reduced or preserved ejection fraction heart failure.
    Van Iterson EH; Johnson BD; Borlaug BA; Olson TP
    Eur J Heart Fail; 2017 Dec; 19(12):1675-1685. PubMed ID: 28990307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure.
    Guazzi M; Tumminello G; Di Marco F; Fiorentini C; Guazzi MD
    J Am Coll Cardiol; 2004 Dec; 44(12):2339-48. PubMed ID: 15607396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baduanjin exercise for patients with ischemic heart failure on phase-II cardiac rehabilitation (BEAR trial): study protocol for a prospective randomized controlled trial.
    Yu M; Li S; Li S; Li J; Xu H; Chen K
    Trials; 2018 Jul; 19(1):381. PubMed ID: 30012193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cardiopulmonary exercise capacity in adult patients with atrial septal defect].
    Suchoń E; Podolec P; Tomkiewicz-Pajak L; Kostkiewicz M; Mura A; Pasowicz M; Tracz W
    Przegl Lek; 2002; 59(9):747-51. PubMed ID: 12632902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.
    Guazzi M; Vicenzi M; Arena R; Guazzi MD
    Circ Heart Fail; 2011 Jan; 4(1):8-17. PubMed ID: 21036891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis.
    De Vecchis R; Cesaro A; Ariano C; Giasi A; Cioppa C
    J Clin Med Res; 2017 Jun; 9(6):488-498. PubMed ID: 28496549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ventilatory response to carbon dioxide output in subjects with congestive heart failure and in patients with COPD with comparable exercise capacity.
    Teopompi E; Tzani P; Aiello M; Ramponi S; Visca D; Gioia MR; Marangio E; Serra W; Chetta A
    Respir Care; 2014 Jul; 59(7):1034-41. PubMed ID: 24046458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
    Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost AE; Engel PJ; Kramer MR; Burgess G; Collings L; Cossons N; Sitbon O; Badesch DB;
    Ann Intern Med; 2008 Oct; 149(8):521-30. PubMed ID: 18936500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute effects of a single dose of phosphodiesterase type 5 inhibitor (sildenafil) on systemic arterial blood pressure during exercise and 24-hour ambulatory blood pressure monitoring in heart transplant recipients.
    Guimaraes GV; d'Avila VM; Pires P; Bacal F; Stolf N; Bocchi E
    Transplant Proc; 2007 Dec; 39(10):3142-9. PubMed ID: 18089340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A critical appraisal of the prognostic value of the VE/VCO2 slope in chronic heart failure.
    Tabet JY; Beauvais F; Thabut G; Tartière JM; Logeart D; Cohen-Solal A
    Eur J Cardiovasc Prev Rehabil; 2003 Aug; 10(4):267-72. PubMed ID: 14555881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with HFrEF.
    Jiang R; Wang L; Zhu CT; Yuan P; Pudasaini B; Zhao QH; Gong SG; He J; Liu JM; Hu QH
    Hypertens Res; 2015 Dec; 38(12):829-39. PubMed ID: 26202179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction.
    Salvioni E; Corrà U; Piepoli M; Rovai S; Correale M; Paolillo S; Pasquali M; Magrì D; Vitale G; Fusini L; Mapelli M; Vignati C; Lagioia R; Raimondo R; Sinagra G; Boggio F; Cangiano L; Gallo G; Magini A; Contini M; Palermo P; Apostolo A; Pezzuto B; Bonomi A; Scardovi AB; Filardi PP; Limongelli G; Metra M; Scrutinio D; Emdin M; Piccioli L; Lombardi C; Cattadori G; Parati G; Caravita S; Re F; Cicoira M; Frigerio M; Clemenza F; Bussotti M; Battaia E; Guazzi M; Bandera F; Badagliacca R; Di Lenarda A; Pacileo G; Passino C; Sciomer S; Ambrosio G; Agostoni P;
    ESC Heart Fail; 2020 Feb; 7(1):371-380. PubMed ID: 31893579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial.
    Behling A; Rohde LE; Colombo FC; Goldraich LA; Stein R; Clausell N
    J Card Fail; 2008 Apr; 14(3):189-97. PubMed ID: 18381181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ventilatory response to exercise improves risk stratification in patients with chronic heart failure and intermediate functional capacity.
    Corrà U; Mezzani A; Bosimini E; Scapellato F; Imparato A; Giannuzzi P
    Am Heart J; 2002 Mar; 143(3):418-26. PubMed ID: 11868046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial.
    Kim KH; Kim HK; Hwang IC; Cho HJ; Je N; Kwon OM; Choi SJ; Lee SP; Kim YJ; Sohn DW
    Am Heart J; 2015 Jun; 169(6):813-822.e3. PubMed ID: 26027619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphodiesterase type 5 inhibition improves arterial stiffness after exercise but not exercise capacity in hypertensive men.
    Attinà TM; Drummond ID; Malatino LS; Maxwell SR; Webb DJ
    Am J Hypertens; 2013 Mar; 26(3):342-50. PubMed ID: 23382484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years.
    Paolillo S; Veglia F; Salvioni E; Corrà U; Piepoli M; Lagioia R; Limongelli G; Sinagra G; Cattadori G; Scardovi AB; Metra M; Senni M; Bonomi A; Scrutinio D; Raimondo R; Emdin M; Magrì D; Parati G; Re F; Cicoira M; Minà C; Correale M; Frigerio M; Bussotti M; Battaia E; Guazzi M; Badagliacca R; Di Lenarda A; Maggioni A; Passino C; Sciomer S; Pacileo G; Mapelli M; Vignati C; Clemenza F; Binno S; Lombardi C; Filardi PP; Agostoni P;
    Eur J Heart Fail; 2019 Feb; 21(2):208-217. PubMed ID: 30632680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.